These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 6441225)
1. New drugs and clinical economics: analysis of cost effectiveness in the assessment of pharmaceutical innovations. Eisenberg JM Rev Infect Dis; 1984; 6 Suppl 4():S905-8. PubMed ID: 6441225 [TBL] [Abstract][Full Text] [Related]
2. Economic analysis of a new drug: potential savings in hospital operating costs from the use of a once-daily regimen of a parenteral cephalosporin. Eisenberg JM; Koffer H; Finkler SA Rev Infect Dis; 1984; 6 Suppl 4():S909-23. PubMed ID: 6441226 [TBL] [Abstract][Full Text] [Related]
3. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections. Plosker GL; Foster RH; Benfield P Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990 [TBL] [Abstract][Full Text] [Related]
5. Economics of home intravenous services. Thickson ND Pharmacoeconomics; 1993 Mar; 3(3):220-7. PubMed ID: 10146945 [TBL] [Abstract][Full Text] [Related]
6. New horizons in pharmaceutical technology. Kirking DM Ann Am Acad Pol Soc Sci; 1983 Jul; (468):182-95. PubMed ID: 10310115 [TBL] [Abstract][Full Text] [Related]
8. Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections. Davis R; Bryson HM Pharmacoeconomics; 1994 Sep; 6(3):249-69. PubMed ID: 10155268 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis. Wessels F; Anderson AN; Ebrahim O S Afr Med J; 1998 Mar; 88(3):251-5. PubMed ID: 9608289 [TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins. Tice AD Drugs; 2000; 59 Suppl 3():29-35; discussion 47-9. PubMed ID: 10845411 [TBL] [Abstract][Full Text] [Related]
12. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
13. [Are drugs worth their cost?]. Martín-Conde JA; Tévar Alfonso E; García García FJ Farm Hosp; 2011 May; 35 Suppl 2():32-9. PubMed ID: 22445507 [TBL] [Abstract][Full Text] [Related]
14. Principles of pharmacoeconomic analysis of drug therapy. Freund DA; Dittus RS Pharmacoeconomics; 1992 Jan; 1(1):20-31. PubMed ID: 10147037 [TBL] [Abstract][Full Text] [Related]
15. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial. Weintraub WS; Culler SD; Kosinski A; Becker ER; Mahoney E; Burnette J; Spertus JA; Feeny D; Cohen DJ; Krumholz H; Ellis SG; Demopoulos L; Robertson D; Boccuzzi SJ; Barr E; Cannon CP Am J Cardiol; 1999 Feb; 83(3):317-22. PubMed ID: 10072215 [TBL] [Abstract][Full Text] [Related]
16. Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins. Davey PG; Malek M Pharmacoeconomics; 1994; 5(Suppl 2):11-9. PubMed ID: 10147284 [TBL] [Abstract][Full Text] [Related]
17. Low-cost therapeutic agents. Uses and abuses. Bunker JP Int J Technol Assess Health Care; 1997; 13(4):521-5. PubMed ID: 9489244 [TBL] [Abstract][Full Text] [Related]
18. Mental health care system optimization from a health-economics perspective: where to sow and where to reap? Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer. Pession A; Prete A; Paolucci G Chemotherapy; 1997; 43(5):358-66. PubMed ID: 9309370 [TBL] [Abstract][Full Text] [Related]